FDMT
NASDAQ4D Molecular Therapeutics Inc.
Price$9.52+0.23 (+2.48%)
01:30 PM07:45 PM
News · 26 weeks52-12%
2025-12-072026-05-31
Mix2790d
- Other12(44%)
- SEC Filings10(37%)
- Insider5(19%)
Latest news
25 items- INSIDEROfficer Kirn David sold $19,258 worth of shares (1,922 units at $10.02) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 1,057,231 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- PR4DMT to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in June. Jefferies Global Healthcare Conference Presentation Date:Wednesday, June 3, 2026Presentation Time:3:10 p.m. ET Goldman Sachs 47th Annual Global Healthcare Conference Presentation Date:Tuesday, June 9, 2026Presentation Time:2:00 p.m. ET Archived copies of the webca
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 12, 2026, the compensation committee of the Company's board of directors granted 14 new non-executive employees 141,100 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employm
- SECSEC Form EFFECT filed by 4D Molecular Therapeutics Inc.EFFECT - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SECSEC Form SCHEDULE 13G filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- SECSEC Form S-3 filed by 4D Molecular Therapeutics Inc.S-3 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SECSEC Form 10-Q filed by 4D Molecular Therapeutics Inc.10-Q - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- PR4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 4FRONT-2 enrollment completion expected in H2 2026; topline data expected in H2 2027 4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026, and SPECTRA DME trial 2-year data expected in H2 2026$458 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform tr
- PR4DMT to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in May. BofA Securities 2026 Healthcare Conference Presentation Date:Wednesday, May 13, 2026Presentation Time:1:40 p.m. PT RBC 2026 Global Healthcare Conference Presentation Date:Tuesday, May 19, 2026Presentation Time:2:35 p.m. ET Archived copies of the webcasts will b
- SECSEC Form DEFA14A filed by 4D Molecular Therapeutics Inc.DEFA14A - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SECSEC Form DEF 14A filed by 4D Molecular Therapeutics Inc.DEF 14A - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 14, 2026, the compensation committee of the Company's board of directors granted five new non-executive employees 67,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into em
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- INSIDERSEC Form 4 filed by Simms Christopher Paul4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Kirn David4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Bizily Scott4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- INSIDERSEC Form 4 filed by Gupta Ashoo4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- SECSEC Form S-8 filed by 4D Molecular Therapeutics Inc.S-8 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SECSEC Form 10-K filed by 4D Molecular Therapeutics Inc.10-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
FDMT FAQ
7 questionsWhat does 4D Molecular Therapeutics Inc. do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment...Where does FDMT stock trade?
4D Molecular Therapeutics Inc. (FDMT) is listed on NASDAQ.What sector and industry is FDMT in?
4D Molecular Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did 4D Molecular Therapeutics Inc. go public?
4D Molecular Therapeutics Inc. (FDMT) completed its IPO in 2020.What are analysts saying about FDMT?
4D Molecular Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $3300.00 price target on 2026-01-28.What companies are similar to FDMT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare FDMT side-by-side with any of them on Quantisnow.How can I track FDMT on Quantisnow?
Quantisnow aggregates 4D Molecular Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FDMT to receive live email and push alerts on every new disclosure.